All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Sudish Murthy, MD, PhD
Disclosure(s): Arthrex: Consultant (Ongoing); Intuitive: Consultant (Ongoing); Medtronic: Consultant (Ongoing); ontarget laboratories: Advisory Board (Ongoing)

Jessica Donington, MD
Disclosure(s): Amgen: Advisory Board (Ongoing); Astra Zeneca global: Advisory Board (Ongoing), Speaker (Ongoing); BMS: Advisory Board (Ongoing), Speaker (Ongoing); Merck: Advisory Board (Ongoing), Speaker (Ongoing); Roche Genentech: Advisory Board (Ongoing), Speaker (Ongoing)

Presentations

1. IO 101—How Do They Work?
   Sandip Patel, MD
   Disclosure(s): Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, Certis, Eli Lilly, Jazz, Genentech, Illumina , Merck, Pfizer, Signatera, Tempus: Advisory Board (Terminated); Amgen, AstraZeneca, A2bio, Bristol-Myers Squibb, Eli Lilly, Fate Therapeutics, Gilead, Iovance, Merck, Pfizer, Roche/Genentech: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated)
    
2. Discussion
    
3. IO 102—Application to Clinical Practice
   Olugbenga Tokunbo Okusanya, MD
   Disclosure(s): Astrazeneca: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Atricure: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Ethicon Endosurgery: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Intuitive: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
    
4. Discussion
    
5. Targeted Therapy 101—How Does it Work?
   Narjust Florez, MD FASCO
   Disclosure(s): Astra Zeneca: Advisory Board (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); BMS: Advisory Board (Ongoing); Daiichi-Sankyo: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Genentech: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Johnson & Johnson: Advisory Board (Ongoing), Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Merck & Co.: Advisory Board (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Advisory Board (Terminated); Novocure: Advisory Board (Ongoing); Pfizer: Advisory Board (Ongoing), Consultant (Ongoing)
    
6. Discussion
    
7. Targeted Therapy 102—Application to Clinical Practice
   Ravi Rajaram, MD, MSc
   Disclosure(s): Cook Medical: Consultant (Terminated); Intuitive Surgical: Proctor (Ongoing); Johnson & Johnson: Consultant (Ongoing)
    
8. Discussion
    
9. Chemotherapy for Lung Cancer in 2025
   Janet Tu, MD
    
10. Discussion